Larsson A, Stenberg K, Ericson A C, Haglund U, Yisak W A, Johansson N G, Oberg B, Datema R
Antimicrob Agents Chemother. 1986 Oct;30(4):598-605. doi: 10.1128/AAC.30.4.598.
9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine (3HM-HBG), (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine ([+/-]2HM-HBG), and cis-9-(4-hydroxy-2-butenyl)guanine (2EN-HBG), new acyclic guanosine analogs structurally related to buciclovir (BCV [(R)-9-(3,4-dihydroxybutyl)guanine]), were evaluated in parallel with buciclovir as anti-herpes simplex virus (HSV) agents. In cell cultures, replication of different strains of HSV type 1 (HSV-1) and HSV-2 was inhibited at nontoxic drug concentrations. The concentrations giving 50% inhibition of plaque formation were, however, dependent on virus strain and cell type. In most cell types, the order of activity against HSV-1 strains was 3HM-HBG greater than (+/-)2HM-HBG greater than BCV greater than 2EN-HBG, whereas the drugs showed an approximately equivalent activity against HSV-2 strains in different cells. The cytotoxic effects of the drugs were also cell type dependent, the order of activity being BCV greater than 3HM-HBG = (+/-)2HM-HBG greater than 2EN-HBG. At growth-inhibitory concentrations, the guanosine analogs BCV, 3HM-HBG, and (+/-)2HM-HBG showed clastogenic effects in human lymphocytes, mainly because of the induction of chromatid breaks. When evaluated for their anti-HSV effects in systemic HSV-1 infections in mice, the order of activity was BCV = 3HM-HBG greater than (+/-)2HM-HBG greater than 2EN-HBG, and in mice infected systemically with HSV-2, only BCV and 3HM-HBG showed efficacy. The differences between efficacy in vitro and in vivo could be explained in part by differences in kinetics of the drugs in mouse plasma, as the more efficacious drugs, BCV and 3HM-HBG, showed lower clearances and longer half-lives than the less efficacious ones, (+/-)2HM-HBG and 2EN-HBG. When used topically against a cutaneous HSV-1 infection in guinea pigs, 3HM-HBG showed an effect equivalent to that of BCV, whereas (+/-)2HM-HBG and 2EN-HBG were inactive. Mechanistically, the guanosine analogs were characterized by a high affinity for the viral thymidine kinase and a low affinity fo a cellular thymidine kinase and by their inhibition of viral DNA synthesis in infected cells.
9-[4-羟基-3-(羟甲基)丁基]鸟嘌呤(3HM-HBG)、(RS)-9-[4-羟基-2-(羟甲基)丁基]鸟嘌呤([+/-]2HM-HBG)和顺式-9-(4-羟基-2-丁烯基)鸟嘌呤(2EN-HBG)是结构上与布昔洛韦(BCV [(R)-9-(3,4-二羟基丁基)鸟嘌呤])相关的新型无环鸟苷类似物,与布昔洛韦作为抗单纯疱疹病毒(HSV)药物进行了平行评估。在细胞培养中,不同株的1型单纯疱疹病毒(HSV-1)和HSV-2的复制在无毒药物浓度下受到抑制。然而,产生50%噬斑形成抑制的浓度取决于病毒株和细胞类型。在大多数细胞类型中,对HSV-1株的活性顺序为3HM-HBG大于(+/-)2HM-HBG大于BCV大于2EN-HBG,而这些药物在不同细胞中对HSV-2株显示出大致相当的活性。药物的细胞毒性作用也取决于细胞类型,活性顺序为BCV大于3HM-HBG = (+/-)2HM-HBG大于2EN-HBG。在生长抑制浓度下,鸟苷类似物BCV、3HM-HBG和(+/-)2HM-HBG在人淋巴细胞中显示出致断裂效应,主要是由于染色单体断裂的诱导。当在小鼠全身性HSV-1感染中评估它们的抗HSV作用时,活性顺序为BCV = 3HM-HBG大于(+/-)2HM-HBG大于2EN-HBG,而在全身性感染HSV-2的小鼠中,只有BCV和3HM-HBG显示出疗效。体外和体内疗效的差异部分可以通过药物在小鼠血浆中的动力学差异来解释,因为更有效的药物BCV和3HM-HBG比效果较差的(+/-)2HM-HBG和2EN-HBG具有更低的清除率和更长的半衰期。当局部用于豚鼠皮肤HSV-1感染时,3HM-HBG显示出与BCV相当的效果,而(+/-)2HM-HBG和2EN-HBG无活性。从机制上讲,鸟苷类似物的特征是对病毒胸苷激酶具有高亲和力,对细胞胸苷激酶具有低亲和力,并能抑制感染细胞中的病毒DNA合成。